DK1004320T3 - Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi - Google Patents

Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi

Info

Publication number
DK1004320T3
DK1004320T3 DK99119057T DK99119057T DK1004320T3 DK 1004320 T3 DK1004320 T3 DK 1004320T3 DK 99119057 T DK99119057 T DK 99119057T DK 99119057 T DK99119057 T DK 99119057T DK 1004320 T3 DK1004320 T3 DK 1004320T3
Authority
DK
Denmark
Prior art keywords
gene
magnesium
administration
improve
gene therapy
Prior art date
Application number
DK99119057T
Other languages
Danish (da)
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Ass Fr Contre Les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Ass Fr Contre Les Myopathies filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1004320T3 publication Critical patent/DK1004320T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK99119057T 1998-09-30 1999-09-30 Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi DK1004320T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98402424A EP0998945A1 (en) 1998-09-30 1998-09-30 Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy

Publications (1)

Publication Number Publication Date
DK1004320T3 true DK1004320T3 (da) 2003-09-15

Family

ID=8235506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99119057T DK1004320T3 (da) 1998-09-30 1999-09-30 Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi

Country Status (10)

Country Link
US (2) US20020019357A1 (es)
EP (2) EP0998945A1 (es)
JP (1) JP5172054B2 (es)
AT (1) ATE243531T1 (es)
AU (1) AU767294B2 (es)
CA (1) CA2284399C (es)
DE (1) DE69909041T2 (es)
DK (1) DK1004320T3 (es)
ES (1) ES2201611T3 (es)
PT (1) PT1004320E (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080897A2 (en) * 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
WO2003000908A1 (en) * 2001-06-21 2003-01-03 Ecole Polytechnique Federale De Lausanne A method for introducing a nucleic acid into a eukaryotic cell
EP1270733A1 (en) * 2001-06-21 2003-01-02 Ecole Polytechnique Federale De Lausanne Method for introducing a nucleic acid into a eukaryotic cell
WO2004075924A1 (ja) * 2003-01-17 2004-09-10 Japan Genome Solutions, Inc. 遺伝子導入促進剤およびそれを含む遺伝子導入用組成物
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
DE102005007744A1 (de) * 2004-06-24 2006-01-19 Shf Communication Technologies Ag Planetengetriebe zur Kombination unterschiedlicher Energiequellen
GB0817393D0 (en) * 2008-09-23 2008-10-29 Givaudan Sa Flavour
EP2405959A4 (en) * 2009-03-13 2013-10-16 Univ Tufts METHODS, APPARATUSES AND KITS FOR INTRODUCING GENETIC MATERIAL INTO LIVING CELLS
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
WO2019222666A1 (en) * 2018-05-17 2019-11-21 University Of Florida Research Foundation, Incorporated Methods and compositions for using metal elements in aav gene therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188069A (ja) * 1984-03-08 1985-09-25 Nakano Vinegar Co Ltd 酢酸菌の環状dνa導入法
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
JPH08308573A (ja) * 1995-05-19 1996-11-26 Ube Ind Ltd 細胞への遺伝子導入方法及びそれに用いられるウィルス感染培地
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
AU752658B2 (en) * 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy

Also Published As

Publication number Publication date
EP0998945A1 (en) 2000-05-10
JP2000143549A (ja) 2000-05-23
US20020019357A1 (en) 2002-02-14
US20020156045A1 (en) 2002-10-24
DE69909041T2 (de) 2004-04-01
JP5172054B2 (ja) 2013-03-27
AU5139799A (en) 2000-04-06
ATE243531T1 (de) 2003-07-15
EP1004320B1 (en) 2003-06-25
DE69909041D1 (de) 2003-07-31
ES2201611T3 (es) 2004-03-16
PT1004320E (pt) 2003-10-31
US6881724B2 (en) 2005-04-19
CA2284399A1 (en) 2000-03-30
AU767294B2 (en) 2003-11-06
CA2284399C (en) 2011-01-18
EP1004320A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
GR3035797T3 (en) Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
DK1004320T3 (da) Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi
WO1996021470A3 (en) Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
MX9701292A (es) Compuestos espiro-azabiciclicos utiles en la terapia.
CA2346119A1 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
IL136101A0 (en) Pharmaceutical compositions containing azelaic acid
EP0848948A4 (en) COMPOSITION FOR LONG-TERM ACTION RECTAL ADMINISTRATION
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
NO158677C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoksazol-derivater.
AU557139B2 (en) Nitrosourea derivatives
ES2150305T3 (es) Composicion anhidra a base de lactulosa.
JPS5598173A (en) Hexahydroo1*44oxazepine*its manufacture and medicine containing same
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
IT1291307B1 (it) Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
AU2699195A (en) Biotin compounds for targetting tumors and sites of infection
CA2175337A1 (en) Method and Composition for Treatment of Patients Having Decompensated Liver Disease
KR880011160A (ko) 벤조피라노피리딘아세트산 에스테르화합물 및 그의 약학적 용도
SU1608870A1 (ru) Способ лечения кистозных новообразований челюсти
UA38447A (uk) Спосіб лікування безбольової ішемії міокарда у хворих на артеріальну гіпертензію
NO996311L (no) Loeselige forlegemidler av paklitaksel